{"id":"NCT02114385","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)","officialTitle":"A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-24","primaryCompletion":"2015-04-22","completion":"2015-04-22","firstPosted":"2014-04-15","resultsPosted":"2018-11-01","lastUpdate":"2018-11-01"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Papilloma Viral Infection"],"interventions":[{"type":"BIOLOGICAL","name":"V503","otherNames":["9vHPV vaccine"]},{"type":"BIOLOGICAL","name":"GARDASIL","otherNames":["qHPV vaccine"]}],"arms":[{"label":"V503","type":"EXPERIMENTAL"},{"label":"GARDASIL","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective\n\nTo demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18","timeFrame":"4 weeks postdose 3 (Month 7)","effectByArm":[{"arm":"V503","deltaMin":758.3,"sd":null},{"arm":"GARDASIL","deltaMin":618.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":7,"countries":["Belgium","Germany","Netherlands"]},"refs":{"pmids":["27354258","29211620"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":248},"commonTop":["Injection-site pain","Injection-site erythema","Headache","Injection-site swelling","Nasopharyngitis"]}}